BioMedNewsBreaks

MondayAug 30, 2021 2:29 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Closes on $3M Convertible Note Led by Rapha Capital

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, has announced that Rapha Capital BioVentures Fund I, LP (“RCBVFI”) led and closed on a new convertible note offering totaling $3 million. The note, which was funded in three tranches, will support the clinical development of Imagin Medical’s flagship product: the i/Blue(TM) Imaging System. In addition, RCBVFI manager and leading urooncologist Dr. Kevin Slawin, MD, was appointed to Imagin’s board of directors, and Imagin also announced an updated website that features the company’s new logo and reflects the company’s…

Continue Reading

MondayAug 30, 2021 1:07 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CLIA Laboratory Receives Accreditation from the College of American Pathologists

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its Philadelphia, Pennsylvania-based Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program, initiated in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program. “Anpac Bio is proud to have received this accreditation,” said Dr. Pandit, the CLIA Laboratory director and CEO of Anpac Bio in the United States. “The College of American Pathologists (‘CAP’) is the gold standard in medical…

Continue Reading

FridayAug 27, 2021 10:44 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Modernizing, Increasing Accessibility to Brain Diagnostics

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with its FDA-cleared NeuroCap(TM) and NeuroEEG(TM), which are already patented in the United States, China and Europe. As the company’s first commercialized devices, they are designed to disrupt the current electroencephalogram (“EEG”) market by offering a cost-effective and disposable alternative to existing solutions. A recent article reads, “Brain Scientific’s development process spans three stages. The first development phase, from 2018 to 2019, resulted in the inception of the company’s portable, clinical-grade, easy-to-use neurological devices.…

Continue Reading

FridayAug 27, 2021 10:25 am

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Closes on $3M Convertible Note

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, announced that it had secured a new convertible note totaling $3 million. Financing for the note, which was comprised of three tranches, was led by Rapha Capital BioVentures Fund I, LP (“RCBVFI”). The company anticipates using the funds  to support the clinical development of its lead product, the i/Blue(TM) Imaging System. According to the company, the proprietary system is poised to increase patient access to this important technology. In addition to the funding, Imagin Medical also named Kevin…

Continue Reading

ThursdayAug 26, 2021 12:31 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Partners with Empower Sleep in Effort to Improve OSA Diagnosis, Treatment

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), is teaming up with Empower Sleep. Vivos and the California-based company, which works to empowering patients with affordable, accessible and personalized telemedicine sleep care, are partnering to offer key diagnostic and medical consultation services to people across North America who suffer from OSA. The partnership will combine core technologies from each company to develop an accessible platform for patients being screened for OSA; the solution will be available throughout North…

Continue Reading

ThursdayAug 26, 2021 10:31 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Releases First-of-Its-Kind Digital Therapeutics Platform to Partner Clinics in North America

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, today announced the release of the minimum viable product version of iSTRYM, its digital therapeutics platform (“DTx”) for psychedelics, into partner clinics across North America. According to the update, the company will begin full commercial deployment to all clinics in the first quarter of 2022. MINDCURE intends to target psychedelic clinics initially and to then expand to integrated clinics, both traditional and psychedelic, and eventually to the broader mental health market. The company forecasts 150 clinics in Canada, the U.S. and…

Continue Reading

TuesdayAug 24, 2021 1:20 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Identifying Significant Trends in Plant Therapy

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is working with researchers to provide a full turnkey solution for clinical studies from start to finish. “As research restrictions throughout the U.S. lift, RYAH Group is standing by, ready to provide IoT hardware, software and data analytics that reduce variations in patient-related clinical trials. One of the areas that the U.S. is poised to explore is cannabis in sports medicine,” reads a recent article. Sports organizations must rethink their strict policies with the legalization of recreational and medicinal cannabis across the country. The good news is…

Continue Reading

TuesdayAug 24, 2021 10:41 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Psychotherapy Training for Upcoming Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced it has completed the training of psychotherapists for its upcoming phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders. According to the update, the training was conducted by Fluence, which is led by researchers and psychotherapists with direct experience in psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals administering psychedelic compounds to patients. “We continue to be amazed by the complexity of neural networks and the array…

Continue Reading

MondayAug 23, 2021 12:52 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Visual Capitalist Article

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was recently featured as a sponsored content provider on the Visual Capitalist. In the article, part one of a two-part series titled, “The History of Psychedelics (Part 1 of 2),” Tryp delves into the evolution of psychedelics from an ancient antidote “to breakthrough medicine with massive therapeutic potential for a wide range of notoriously hard-to-treat diseases.” “With these strict legal changes around the world, the psychedelics industry became largely inactive. But today, an explosion of unprecedented…

Continue Reading

MondayAug 23, 2021 10:38 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for Registration Testing of Its Multicancer CDA Device

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has filed with China’s National Medical Products Administration (“NMPA”) for registration testing of its class III, multicancer detection medical device; the device, which has been tested and evaluated extensively, features AnPac’s proprietary Cancer Differentiation Analysis Technology (“CDA”). The company has reported that all preclinical trials and tests conducted through July 2021 have produced positive results. Approval of the NMPA application would allow the device to be used to assist in the diagnosis of 11 different types of cancer, including lung, esophageal, gastric, rectal, colon,…

Continue Reading